Loading...
Market
What regulatory designation will Genentech's RGT-4198 CDK inhibitor receive by September 30, 2025?
2
Resolution / Starting Odds
Breakthrough Therapy • 25%
Fast Track • 25%
Orphan Drug • 25%
None • 25%
FDA announcements and Genentech's press releases
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850M
Sep 30, 2024, 11:05 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential additional milestone payments. This acquisition includes CDK inhibitors such as RGT-4198, which is in phase 1 and targets CDK4/2/6 with some CDK9 activity. The deal is part of a Definitive Purchase Agreement and is expected to enhance Genentech's oncology pipeline, particularly in the treatment of breast cancer. Roche, the parent company of Genentech, is also projecting more than 3 billion Swiss francs ($3.6 billion) in peak sales from its drug candidates in obesity and diabetes, acquired from Carmot Therapeutics.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Breast cancer • 25%
Lung cancer • 25%
Colorectal cancer • 25%
Other cancer types • 25%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Breakthrough Therapy Designation • 25%
Orphan Drug Designation • 25%
Priority Review • 25%
No additional designations • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%